Clinical Trial Update: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing alemtuzumab with Rebif (interferon beta-1a) in relapsing-remitting multiple sclerosis has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Lemtrada (alemtuzumab)
• Rebif (interferon beta-1a)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED | Results posted: 2015-01-08